Abstract | About one in 300 women will be diagnosed with breast cancer before the age of 40. Advances in screening have not had an impact on mortality in women who are too young to be candidates for screening. Risk factors for early breast cancer include a lean body habitus and recent use of an oral contraceptive. Breast cancers in very young women are typically aggressive, in part owing to the over-representation of high-grade, triple-negative tumours, but young age is an independent negative predictor of cancer-specific survival. Very early age-of-onset also correlates strongly with the risk of local recurrence and with the odds of contralateral breast cancer. Given the high risks of local and distant recurrence in young women with invasive breast cancer, most (if not all) young patients are candidates for chemotherapy. It is hoped that by increasing breast cancer awareness, the proportion of invasive breast cancers that are diagnosed at 2.0 cm or smaller will increase and that this will lead to a reduction in mortality.
Introduction
Approximately 18% of breast cancer cases in Canada occur in women before the age of 50 and 4% occur before the age of 40.
1 A Canadian woman has a 0.4% chance of being diagnosed with breast cancer by the age of 40, compared with 1.6% at the age of 50 and 9.2% over her lifetime. 1 The risk for developing breast cancer before the age of 40 is similar throughout the world (Table 1) surprisingly the risks in Canada, Japan, Bangladesh and Nigeria are approximately the same. The risk of veryearly onset breast cancer in Canada is a little higher than the world average of 0.3%. 1 The overall burden of breast cancer in the developing world is growing 2 -this is thought to be a consequence of westernization, of lowering age of menarche, declining fertility and of increasing life expectancy-however, these global trends have had relatively little impact on the rates of very-early onset cancer ( Figure 1 ). In most countries, the rate of breast cancer in women under 40 has been stable for the past 20 years ( Figure 1 ).
Breast cancer in young women presents a challenge, in part because it is rare, but also because of the paucity of modifiable risk factors and the lack of screening for young women. The risk of breast cancer below the age of 40 is less than 1% in all countries 1 and this risk is too low to mobilize communities to organize screening programmes. Several characteristics of breast cancers in young women make them difficult to treat, including a high proportion of triple-negative cancers, 3 high risks of local recurrence 4 and of contralateral breast cancer, 5 and a high mortality rate. 6 In this Review, I focus on the descriptive and analytical epidemiology of breast cancer in women under the age of 40, and on various clinical aspects of the disease. I do not discuss the psychosocial aspects of an early diagnosis of breast cancer, nor the impact of breast cancer treatment on fertility or quality of life; these topics have been well-reviewed elsewhere. 7 
Categories of young onset breast cancer
In many studies, patients with breast cancer are divided into categories of younger than age 50, versus age 50 and above. This is roughly equivalent to dividing patients into premenopausal and postmenopausal groups, but age-ofonset is easier to establish than menopausal status. In some studies and review articles, early onset cancer is defined as before age 35 or before age 45, but for consistency and simplicity I will focus on cases below age 40. Among women with premenopausal breast cancer, there are reasons to believe that further subdivision into those with very-early onset disease (before age 40) and relatively early onset disease (40-49 years) is meaningful; 8 here the focus is on very-early onset disease.
International comparisons
Rates of breast cancer under the age of 40 generated by GLOBOCAN can be used to make international comparisons and to review secular trends. 1 The differences in rates between countries and over time are unlikely to reflect screening practices, because nowhere is mammographic screening routinely offered before the age of 40, nor are the rates affected by the use of hormonereplacement therapy (HRT) as the patients have not reached menopause. However, the completeness and accuracy of reporting, as well as the stage distribution of cancers at diagnosis are important factors. The annual rates of early onset breast cancer around the world are relatively stable (Figure 1 ). Fertility rates are not predictive of early onset breast cancer ( Figure 2a,b) ; despite similar rates of early onset breast cancer (Table 1) , Japan has a fertility rate of 1.2, versus 1.6 for Canada, 2.6 for Bangladesh and 4.7 for Nigeria. 9 Age of menarche is much less predictive of early onset breast cancer than it is for postmenopausal breast cancer (Figure 2c 
Risk factors
It is tempting to think that factors that occur early in life would be more predictive of early onset breast cancer than of postmenopausal breast cancer, but this has not been proven. Many studies of very-early onset breast cancer are hampered by small sample sizes. It is also very difficult to study risk factors that act early in life, because in a case-control study, recall and recall bias are potential problems, and in cohort studies, the follow-up period must span the gap from childhood to adulthood. The public is much engaged in the debate regarding the contri bution of various lifestyle factors and environmental contaminants to the risk of breast cancer (leading to an Act of Congress; EARLY [Education and Awareness Requires Learning Young] in 2010, reviewed below), 10 but our knowledge here is limited. Some factors might influence risk in North America to a small extent, but it is unlikely that local factors can help explain the similar rates of early onset breast cancer throughout the world and over time (Figure 1 ).
Intrauterine exposures
Breast cancer is almost non-existent before age 25, but it has been proposed that important risk factors might operate before the age of 18; that is, the period of greatest susceptibility predates the period of greatest risk by several decades. 11 Birth weight, growth rate in childhood and attained height are all risk factors for premenopausal breast cancer, but the effects sizes are small. 12, 13 Trichopoulos and his colleagues contend that prenatal influences may be relevant for breast cancer. 11, 14, 15 This contention is not meant to imply that babies are exposed unduly to carcinogens, rather, they have assessed the role that endogenous steroidal and non-steroidal hormones and growth factors might have on the normal breast. A refinement of this model is that the size of the breast-stemcell pool is determined early in life, under the influence of pre natal and early childhood hormone levels, and that the number of stem cells predicts the risk of breast cancer thereafter. 8, 11, [15] [16] [17] The stem cell model proposes that stem-cell self renewal may be symmetric-giving rise to two daughter stem cells-or asymmetric-giving rise to one stem cell and one differentiated cell. Under this model, symmetric division would be necessary to expand the stem-cell pool and if symmetric divisions were more vulnerable to mutation than asymmetric divisions, then this would explain the period of relative sensitivity to mutagens in adolescence. Baik et al. 15 found positive corre lations between cord blood levels of insulin-like growth factor I, insulin-like growth factor-binding protein 3, oestriol and testosterone and the concentration of cord blood cells that expressed stem-cell associated markers. 15 Given that one cannot yet measure concentrations of stem cells in the adult human breast, and that it is not feasible to correlate neonatal hormones with adult cancer risk (let alone with breast-stem-cell numbers) perhaps Trichopoulos and Lipworth were right when, in 1995 they concluded that the problem was intractable. 14 Recently, intrauterine exposure to diethylstilbestrol (DES) was found to increase the risk of premenopausal breast cancer, 18 but none of the 82 cases of invasive breast cancer observed in the cohort of exposed women was diagnosed before the age of 40.
Diet, exercise and BMI There have been several studies of exercise in young women in relation to breast cancer risk. On the whole, these do not present compelling evidence that exercise is preventive. In 1994, Bernstein et al. 19 reported a case-control study that showed the average number of hours spent in physical exercise was associated with a reduced risk of breast cancer. 19 The odds ratio (OR) of breast cancer among women who averaged 3.8 or more hours per week of physical exercise was 0.42 (95% CI 0.27-0.64) relative to inactive women. Unfortunately, this promising early finding was not confirmed. In a second case-control study (1,688 cases and 1,505 controls) early onset breast cancer risk was not associated with recreational exercise. 20 In the Nurses' Health Study, Rockhill et al. 21 found no association between physical There have been few dietary studies of breast cancer conducted in young women, but it is important to note that a large observational study of dietary fruit and vegetable consumption 23 and randomized trials of dietary fat reduction 24, 25 have been disappointing in that they did not support a potentially beneficial role for dietary change. Obesity is a risk factor for postmenopausal breast cancer-presumably through increased levels of circulating oestrogens caused by aromatization of androgens in fatty tissues 26 -but a high BMI is protective against breast cancer in premenopausal women. 26 The reason for this protection is unclear. Almost all of the literature on physical activity and obesity are based on western populations and it will be of interest to see if there are different associations in women from East and South Asia, who face a similar risk level.
Reproductive risk factors

Oral contraceptives
Oral contraceptives are a risk factor for premeno pausal breast cancer, but the actual risk increase associated with use of the pill is small. 27 The Collaborative Group on Hormonal Factors in Breast Cancer analysed data on 53,297 cases and 100,239 controls; current users of oral contraceptives were at increased risk of breast cancer (relative risk [RR] = 1.24; 95% CI 1.15-1.33), but the risk diminishes after stopping pill use, and 10 years after last use there was no apparent residual risk. There is no signi ficant excess risk of having breast cancer diagnosed 10 or more years after stopping use (RR = 1.01; 95% CI 0.96-1.05). 27 In a case-control study of 265 breast cancer cases diagnosed at age 34 and below, recent use of oral contraceptives and a family history of breast cancer were significant risk factors. 28 
Parity
Increasing parity is protective against breast cancer in the general population, but the effects of early birth and parity are less in women diagnosed with breast cancer before the age of 40.
29 By contrast, there is a transient increase in the risk of breast cancer after giving birth. 30 This is thought to be due to the mitogenic effect of high oestrogen levels during pregnancy. 31 
Breastfeeding
Breastfeeding has been found to be protective against breast cancer in most studies, in both premenopausal and postmenopausal women, but the magnitude of the protective effect varies between studies. In a case-control study from the UK, the relative risk of breast cancer in women below the age of 36 declined by 22% for each year of breastfeeding. 32 In a large meta-analysis, the decline in breastfeeding on premenopausal breast cancer risk was much more modest; the risk decreased by 4.3% for every 12 months of breastfeeding for both premenopausal and postmenopausal women. 33 The association with breastfeeding is present in women from developed and develop ing countries and promoting breastfeeding worldwide may have potential for reducing risk.
Genetic factors
Approximately 3% of all breast cancers in the UK are attributable to mutations in BRCA1 or BRCA2. 34 The proportion with BRCA mutations is higher for breast cancers that occur before the age of 36, ranging from 6% to 9%; 35, 36 and only a small minority of women with 
REVIEWS
early onset cancers carry a BRCA1 or BRCA2 mutation. Most young women with a strong family history of breast cancer do not carry a BRCA1 or BRCA2 mutation. Breast cancers that occur in the Li-Fraumeni syndrome often affect women in their twenties and thirties. 37 The causative gene is TP53, 38 but mutations in TP53 are very rare in unselected women with early onset breast cancer, 39, 40 and most women with breast cancer and a TP53 mutation have a family history suggestive of the Li-Fraumeni syndrome (childhood cancers of the adrenal cortex, sarcomas and brain tumours). It is interesting that in Brazil, a mutation in TP53 is carried by one in 300 women, 41 but the contribution of this founder mutation to early onset breast cancer in Brazil seems to be low. 42 The other relevant gene is CHEK2; women with a constitutional mutation in CHEK2 are at approximately double the risk for breast cancer, 43 but the age of onset in these cases is not atypically young. 44 Hereditary cancers typically present at a young age and one expects the proportion of hereditary cancers to increase with diminishing age of diagnosis. A positive family history of breast cancer is an important risk factor for breast cancer in very young women. In a study by Althuis et al., 28 a family history of early onset breast cancer was strongly associated with risk among women <35 years (RR = 3.22). In the largest study of its kind involving 58,209 women with breast cancer and 101,986 controls, the relative risk of breast cancer associated with a first-degree relative with breast cancer increased with decreasing age of breast cancer, both in the index case and in the relative. 45 However, a positive family history is present in only a minority of early onset breast cancer cases and, therefore, few can be attributed to a hereditary factor. Despite a recent revolution in genetic sequencing technology, the genetic basis for most of these cancers remains to be explained.
Radiation
Exposure to ionizing radiation is an established (albeit rare) risk factor for premenopausal breast cancer. Much of what we know about the hazards of radiation come from studies of women exposed to high doses as a result of the atomic bomb explosions or childhood therapeutic radiation. [46] [47] [48] [49] [50] Risk estimates for lower doses are based on extrapolation from these studies. The risk of breast cancer depends on the age of exposure, the attained age and the radiation dose. Among women treated for Hodgkin disease with mantle radiation before the age of 25, the risk of breast cancer is approximately 10% by the age of 45 and may reach as high as 29% by the age of 55. 48 Radiation exposure before the age of 18 is particularly hazardous and radiation has not been shown to be a risk factor for women exposed after the age of 50. 46 It is often assumed that radiation is more likely to be hazardous during adolescence (that is, during the period of breast proliferation) than during childhood (when the breast tissue is quiescent) but this premise has been challenged. 46 The relative risk of breast cancer associated with prior exposure to radiation is higher for early onset breast cancers (before age 35) than for cancers occurring at a later age. 50 It is believed that ionizing radiation acts as a carcinogen through the induction of DNA mutations. It is proposed that the majority of mutations in breast cells occur at random (and are not related to the environment) but radiation might be an important exception. 17 Reproductive risk factors modify the risk of radiationinduced breast cancers. 51 One might suppose that women with an inherited defect in a gene such as BRCA1 and who have compromised DNA-repair capacity might be sensitive to radiation, but (fortunately) women with exposure to both a BRCA mutation and high doses of radiation are rare, and the hypothesis is unproven. The principal risk factors for early onset breast cancer are listed in Box 2.
Clinical outcomes
It is now widely accepted that women diagnosed with breast cancer under the age of 40 have, on average, inferior clinical outcomes compared with women diagnosed at later ages. It seems that this is related more to age per se than to menopausal status because, in many studies, age is a strong risk factor for mortality among women with premenopausal breast cancer. 8 It is natural to wonder if the inferior outcome is attributable to an over-representation of pathological features that are associated with poor prognosis in young women, or if age is an independent risk factor. The distinction is important because if age is independent of other prognostic factors then young women with breast cancer might benefit from treatments other than those offered to older women with the same tumour profile. If not, then treatment should be guided primarily on the basis of tumour grade, stage and so on.
After adjusting for other prognostic factors, Bharat et al. 6 estimated the risk for breast cancer recurrence for women diagnosed below the age of 40 as 1.53-fold higher than the risk for those diagnosed at 40 years or older (95% CI 1.37-1.74). In the study of Voogd et al., 4 the risk of death following breast-conserving surgery for patients aged 35 or younger was twice that of women aged 60 or older. It is noteworthy that in many studies, in terms of prognosis, the division of age into <40 and >40 is more discriminatory than dichotomizing at age 50. For example, in the recent study by Azim et al., 8 women under 40 years had a much worse recurrencefree survival than women over the age of 40, but the survival rates in the age groups 41-52 and 53-64 were nearly identical.
The most common metric for describing clinical course is age-specific survival, but it is also of interest to consider the different components of prognosis in relation to age, such as risk of local recurrence, time to local recurrence, time to distant recurrence and time from recurrence to death. It is also instructive to ask to what extent mortality rates differ because of varying response to chemotherapy.
Pathology
Fewer women under the age of 40 are diagnosed with ducal carcinoma in situ than older women, 52 but likely this is caused by the lack of regular mammographic screening in women before the age of 40 women under 40 years: 66% were ER-positive, 31% were HER2-positive, 55% were high grade and 21% were triple negative (ER, PR and HER2 negative). Paradoxically, compared with older women, young women have relatively high proportions of both triple-negative cancers and HER2-positive cancers; 3, 8, 53, 54 this is due to the relative paucity of ER-positive (luminal A) cancers.
One would predict, correctly, based on the age distributions of grade and adverse pathological features, that young women should have a relatively poor prognosisbut these factors do not account entirely for the poor survival, and young age seems to be an adverse factor independent of the standard pathological features. 4, 6, 55, 56 Nixon and colleagues 56 analysed data from 1,398 patients treated with breast-conserving therapy between 1968 and 1985, including 107 who were younger than 35. After a median follow-up period of 99 months, after adjusting for standard pathological features, young age (<35 versus >35) remained a significant predictor of time to recurrence (RR = 1.70) and of overall mortality (RR = 1.50). Gnerlich et al. 57 reviewed cancers in the SEER (Surveillance Epidemiology and End Results) database and compared breast cancer mortality rates in women younger than 40 years and women 40 years and older. In this analysis, the survival difference was greater among women with stage I cancer than for more-advanced stages. This intriguing observation suggests that among young women, breast cancers have a propensity to spread when small. This was confirmed by Xiong et al. 58 who reviewed the survival experience of patients treated at the MD Anderson Cancer Center. The difference in survival between very-young onset (<30) and older-onset cases was marked for patients with stage I and stage II cancers, but not for patients with later stage cancers. Tumour size is an equally important predictor of mortality in young and old women, 59 and theoretically, early detection should benefit both age groups equally.
It is not now possible to explain the survival differences entirely on the basis of different biological parameters of the tumour, but this may change as additional prognostic markers are identified. Anders et al. 54 evaluated the RNA expression levels of hundreds of genes in breast cancer and correlated the expression levels with survival. They found that EGFR expression levels were relatively high in younger women and correlated with poor prognosis and levels of EGFR expression added signi ficant predictive power beyond the traditional markers. Similarly, Azim and colleagues 8 assessed geneexpression signatures in young (<40) and older (>40) patients with breast cancer using an in silico approach and correlated these signatures with survival. They found that young age per se was an adverse prognostic factor (hazard ratio for mortality = 1.43; P = 0.004) after adjusting for gene signatures and conventional clinical prognostic features. The largest effect of age on survival was within the subgroup of patients with ER-positive and HER2-negative cancer. This finding is clinically relevant because these are the women who are least likely to receive chemotherapy. Clinical and pathological features of early onset breast cancer are summarized in Box 3.
Local recurrence
Young age at diagnosis is a risk factor for both ipsi lateral recurrence 60 and for contralateral breast cancer. 61 In the large European Organisation for Research and Treatment of Cancer (EORTC) group trials, younger age was a risk factor for local recurrence. Compared with women over 50 years of age, those diagnosed with breast cancer under 35 years of age experienced a hazard rate of 2.8 (95% CI 1.4-5.6) for local recurrence. 60 Voogd et al. 4 reported that the local recurrence rate after breastconserving surgery and radiotherapy in women aged 35 or younger was 9.2-fold higher than that of women aged 60 and over (hazard ratio = 9.24; 95% CI 3.7-23). The 10-year actuarial rate of local recurrence in women aged 35 and younger was an unacceptably high 35%, suggesting that the combination of radiotherapy and breast-conserving surgery is probably inadequate for local control. It is interesting that, in this study, women aged 35 to 60 had similar rates of local recurrence to women aged 60 and above. 4 It is important that when breast-conserving surgery is discussed with very-young women, age-specific estimates for recurrence are presented. Risk factors associated with death following local recurrence are time from diagnosis to local recurrence, positive lymph-node status and age of initial diagnosis. [60] [61] [62] [63] It is noteworthy that the impact of young age on outcome is much greater for local recurrence and contralateral breast cancer than it is for distant recurrence or mortality, and this associ ation suggests that factors related to the breast itself might be relevant.
Contralateral breast cancer
The absolute risk of contralateral breast cancer is similar for young women and for older women. 64 However, in terms of relative risk, the difference is large. 62 Age of diagnosis is one of the strongest risk factors for contralateral breast cancer. If a woman develops invasive breast cancer in her left breast at age 30, the probability of her developing breast cancer in her right breast by age 40 is about 5% (0.5% per year). 64 The cumulative risk of breast cancer to age 40 in Canada is only about 1 in 250 (one in 500 for the right breast and one in 500 for the left breast). 1 If we compare the two rates, we get a relative risk of 25 for contralateral breast cancer before the age of 40.
Factors related to the breast The risks for both local recurrence and contralateral breast cancer are much higher for young women than for older women. 60, 61 This suggests that age-related factors that are related to the composition of the breast might contribute to cancer risk. Mammographic density is a risk factor for breast cancer 65 and for breast cancer recurrence; 66 mammographic density is higher, on average, in young women than in older women. 67 Recent molecular studies suggest that the gene-expression patterns in the breast cancer stroma may predict distant recurrence. 68 It will be of interest to establish if the gene signatures from normal breast tissue are different in young women who do and who do not develop breast cancer (and in particular for women who develop contralateral breast cancer).
The possibility that factors intrinsic to the breast are important determinants of breast cancer risk in young women has been raised in an attempt to explain the high relative risk of contralateral breast cancer in young women and the paucity of environmental and genetic risk factors. 69 Studies on the development of the normal breast and of normal and preneoplastic stem cells and progenitor cells may be informative here. Several studies have also shown that stromal components of the surrounding breast tissue have prognostic value. Beck et al. 70 found that stromal features were predictive of survival following a diagnosis of breast cancer. In addition, Azim et al. 8 observed that breast cancers from young women (<40) were enriched for genes that are typically expressed in luminal progenitor cells, mammary stem cells, inclu ding RANKL and KIT, and suggest that targeting these developmental pathways (for example with a RANKL inhibitor) might have therapeutic value.
Treatment
The relatively poor prognosis of young women with very-early onset breast cancer raises a critical question-should women diagnosed before the age of 40 be treated differently than older women? For example, should all very-young women with invasive breast cancer receive chemotherapy, regardless of tumour size, grade or nodal status?
A second question is whether or not women with very-early onset breast cancer are candidates for breastconserving surgery. Given that no compelling data from randomized trials show that there is an inferior outcome for young women treated with breast-conserving surgery, compared to mastectomy, the arguments in favour of mastectomy are indirect: first, the risk of local recurrence is much higher for young women than for older women; second, the mortality rate for young women after a local recurrence is very high (and is similar to the rate for young women who experience a distant recurrence). Also, the younger the woman, the greater is her life expectancy and the more likely is she to develop a second breast cancer.
This risk of contralateral breast cancer is also relevant, in particular if contralateral preventive mastectomy is being considered. Risk factors for contralateral breast cancer include young age at diagnosis, 64 and having a BRCA1 or BRCA2 mutation. 71 However, for a 30-year-old woman with breast cancer, the 10-year cumulative risk of contralateral breast cancer is only about 5%. 64 It has been shown that contralateral mastectomy reduces the incidence of contralateral breast cancer in women with a hereditary predisposition 71 and in women at high risk, 72 but there are few data on mortality benefit. If contralateral mastectomy were to reduce breast cancer-specific mortality this would be expected to be the result of fewer deaths from contralateral cancers. In a study based on SEER data, Bedrosian et al. 73 reported a significant reduction of 5-year mortality of 32% in young women (ages 18-49) with stage I or II ER-negative breast cancer who underwent contralateral mastectomy. This result is not easily explained, given that only 2-3% of the patients would be expected to develop a contralateral breast cancer in such a short period and far fewer patients would be expected to die from it. The majority of deaths from contralateral breast cancer are expected to occur in the second decade after treatment, 74 and it will require a long-term study (>20 years of follow up) to properly evaluate the mortality benefit of contralateral mastectomy.
A third question is whether there is benefit from ovarian ablation that goes beyond that of chemotherapy and hormone therapy. In BRCA1 and BRCA2 carriers, oophorectomy is recommended to prevent cancer recurrence, contralateral breast cancer and new primary ovarian cancer, 75 but in non-carriers, there is less evidence in support of the procedure.
The Early Breast Cancer Trialists Collaborative Group 76 study confirmed the benefit of chemotherapy in treating breast cancer in women diagnosed before the age of 50. Overall, the mortality rate was reduced by 38% with adjuvant chemotherapy. Kroman et al. 77 extended this study by subdividing the early onset women into 5-year age intervals. The greatest benefit of chemo therapy was seen for women aged 35 or younger at diagnosis (OR for no chemotherapy versus chemo therapy 2.2; 95% CI 1.6-2.9). The benefit of chemotherapy was present for veryyoung women with node-negative breast cancer and with small breast cancers. In this analysis of 2,600 young women, there was no subgroup that did not benefit from chemotherapy. Young age was a risk factor for recurrence, but the adverse effect of age on survival was greatly attenuated in women treated with chemotherapy. Interestingly, this finding is analogous to the situ ation in BRCA1-associated cancers, wherein the adverse effect of a BRCA1 mutation is present only in women not treated with chemotherapy. [78] [79] [80] Kroman et al. 77 agree with the 1995 recommendation of the International Consensus Panel of the Treatment of Breast Cancer that chemotherapy should be offered to all women younger than 35 with invasive breast cancer. 81 Freedman and Partridge argue that not all young age patients with breast cancer should receive chemotherapy, but as convention dictates, the choice of therapy should be based on a woman's specific recurrence risk. 82 The situation is easier for hormone receptor-negative cases, where there are fewer treatment options. For young women with receptor-positive cancer, alternates to cytotoxic chemotherapy include tamoxifen, ovarian ablation (surgical or chemical suppression) and in some cases, the addition of an aromatase inhibitor. Several studies suggest that for women with low-risk hormone receptor-positive disease, endocrine therapy might be as effective as cytotoxic chemotherapy.
83,84
Strategies for prevention
There is much interest in preventing breast cancer, but so far there is little practical advice we can offer to a young woman. Most information (screening, avoidance of HRT and alcohol) is directed at preventing postmenopausal breast cancer. The impact of oral contraceptives in terms of relative risk and population-attributable risk is similar to that of HRT, but the excess risk of oral contraceptives is much smaller than the risk of HRT because the baseline risk of breast cancer in young women is low. Obesity is not a risk factor for premenopausal breast cancer and there is little evidence that restricting calories or advocating exercise will have any impact. In spite of a dearth of practical knowledge, the EARLY act was passed in 2010 by the US Congress with the stated goals of educating and increasing breast cancer awareness among women younger than age 45. 10 It is hoped that through breast awareness, more breast cancers will be detected when curable and that by educating women about modifiable risk factors, we might promote positive behavioural change. Unfortunately, the premise that we can prevent breast cancer risk by eliminating risk factors is unproven. Some risk factors are very rare (for example, radiation exposure for Hodgkin disease treatment) for some, the impact on absolute risk is modest (for example, oral contraceptives), some are unchangeable (such as family history and age at menarche) and for some, promoting change is probably unwise (such as gaining weight or advocating early pregnancy).
In contrast to avoiding risk factors, promoting breastfeeding is potentially helpful. The protective effect of breastfeeding is seen in young women and in women from many countries. However, it is not clear to what extent, if any, women can become motivated to breastfeed, or to prolong breastfeeding based on a modest antici pated decline in the risk of breast cancer many years in the future.
The argument for breast cancer awareness is more compelling. Currently, routine mammographic breast screening is not recommended for women under the age of 40. Nevertheless, if we accept that breast cancer should be diagnosed at the smallest possible size, and that tumour size is a good predictor of mortality, then reducing mean tumour size will have a beneficial effect on mortality. The single large randomized trial of breast self examination did not show a reduction in breast cancerspecific mortality, but this is not unexpected, given that the trial did not lead to a significant reduction in the size of the cancers detected. 85 The trial was conducted in Shanghai in 1989 and it is premature to conclude from a single study that formal breast self examination (or better 'awareness') will not have an impact on mortality. In two cross-sectional studies from Japan, breast cancers that were detected by self examination were smaller, on average, than those that presented clinically. 86, 87 In the study by Ogawa et al., 86 the average size at diagnosis was 2.5 cm for women who performed monthly self examination, compared to 3.5 cm for those who did not. A shift of this size is expected to result in a survival difference of at least 15%. At the Women's College Hospital in Toronto, the average size at diagnosis of palpable breast cancers declined from 2.7 cm to 2.3 cm from 1986 to 1999, whereas the average size of mammogram-detected breast cancers was stable over the same time period. 59 Breast self examination is promoted throughout the world as an inexpensive alternative to mammography and it is unfortunate that there is little new evaluative research being done in this area. In North America, the average size of breast cancer varies in young women according to their ethnic background (Figure 3) . The difference in 5-year overall survival by ethnicity is relatively small for breast cancers of 2.0 cm and smaller, but is substantial for larger cancers (Figure 4) . Among young women, the median tumour size at presentation has dropped more among white women than among black or Hispanic women since 1983 ( Figure 3) ; this suggests that the racial difference in stage at presentation is not explainable by bio logical factors and that there is still much to be gained by increasing breast awareness, particularly in women with an ethnic minority background.
The enthusiasm for increasing breast cancer awareness by lay advocates and by Congress is not matched by an enthusiasm for chemoprevention. Currently, only Year Median tumour size (mm) 1 9 8 7 1 9 8 8 1 9 8 9 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 tamoxifen is approved as chemoprevention for women in North America, but it used rarely and almost never used in young women. 88, 89 This usage is perhaps not surprising, given that the average risk of breast cancer before the age of 40 is one in 250 and up to age 50 is one in 60 and most women do not see themselves as high risk. However, even in women with a BRCA1 mutation (where the average risk up to age 50 is about 50%), fewer than 10% of eligible healthy women opt to take tamoxifen. 90 Many women are concerned about the adverse effects, even though serious adverse effects are rare in young women. 91 Currently, the recommended preventive dose is 20 mg daily for 5 years, but it is of interest to see if shorter durations and/or lower doses are also effective.
Conclusions
Rates of breast cancer in women under age 40 are remarkably stable across time and by country of residence, suggesting that the most important contributing factors are not local exposures. Known risk factors for early onset breast cancer are few and can only account for a very small proportion of cases. Our knowledge of genetic factors has increased dramatically since 1994, but only about 10% of early onset breast cancers can be attributed to inherited predisposition.
Young women have a relatively poor prognosis compared with older women, and their poor survival experience cannot be explained by differences in the distri bution of known adverse pathological features, such as tumour grade, ER status and HER2 status. However, other factors, such as EGFR expression, or undis covered markers, may eventually better explain prognosis such that age will no longer be an independent prog nostic factor. Early age at diagnosis is one of the strongest predictive factors for local recurrence, contralateral breast and for mortality after recurrence. For women below the age of 35, the risk of local recurrence after breastconserving surgery and radiotherapy remains high and the option of mastectomy should be discussed. Chemotherapy has been shown to benefit women in this age group and, to date, it is not proven that there is a subgroup of breast cancer patients under the age of 35 for whom chemotherapy is not indicated.
The impact of young age on the risks of both ipsilateral and contralateral breast cancer exceeds the impact on mortality and suggests that host-related factors, in particular those related to the breast tissue, such as breast density or possibly the number of mammary stem cells, are important risk factors that decline with age. The strong inflection of recurrence risk at age 40 suggests that the age effect is independent of hormonal changes at menopause.
It is unlikely that we can prevent breast cancer in young women by eliminating risk factors. More promising areas of research include ways to promote breastfeeding, improve early detection, expand genetic screening and tailor chemoprevention. There is potentially much to be gained by increasing the proportion of breast cancers that present at 2 cm or smaller, particularly among ethnic minority women.
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